Biomarker-Driven Lung Cancer

>

Latest News

KRYSTAL-12 Study of Adagrasib Meets Primary End Point in KRAS G12C NSCLC
KRYSTAL-12 Study of Adagrasib Meets Primary End Point in KRAS G12C NSCLC

March 29th 2024

The KRYSTAL-12 trial of adagrasib showed positive results for progression-free survival and tumor response in KRAS G12C-mutated non-small cell lung cancer.

Selection of First-Line NSCLC Therapy Influenced by Delayed Testing
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing

March 8th 2024

Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment
Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment

February 19th 2024

FDA Grants Avutometinib/Sotorasib FTD in KRAS-Mutated NSCLC
FDA Grants Avutometinib/Sotorasib FTD in KRAS-Mutated NSCLC

January 19th 2024

More News